Introduction
In circulating blood, platelets are continuously exposed to von Willebrand protein (vWF)' and fibrinogen, but only bind these proteins during the formation of hemostatic plugs at sites of vascular injury. vWF is a polymeric plasma glycoprotein that plays a central role in the events ofprimary hemostasis. Binding both to collagen (1) (2) (3) (4) (5) (6) (7) (8) and to the platelet surface (9) (10) (11) (12) (13) (14) , it links the platelet with the subendothelium at sites of vascular injury (15) (16) (17) . Although incubation of platelets in vitro with polycations, such as the antibiotic, ristocetin, promotes vWF binding to glycoprotein Ib, the physiologic regulator of this binding has not been elucidated. In contrast, it has been clearly shown that exposure ofplatelets to ADP and to a product ofthe coagulation cascade, thrombin, promotes the binding of fibrinogen and vWF to glycoprotein Ilb/IIa ( 13, 14, 18) . Because the events of priAddress reprint requests to Dr. Loscalzo. Receivedfor publication 30 mary and secondary hemostasis are temporally related and physically coupled, it is likely that one ofthe intermediates generated during coagulation stimulates vWF binding to glycoprotein Ib, as well.
In addition to the bifunctional role offibrinogen as a platelet adhesive protein and a thrombin substrate, there are several other examples of interactions between platelets and coagulation proteins of importance. Platelets bind Factors Va and Xa and provide a surface that accelerates prothrombin conversion (19) (20) (21) . Thrombin not only converts fibrinogen to fibrin, but also induces platelet activation and secretion. Platelets are also a source of Factor V (22) , fibrinogen (23) , and vWF (24, 25), the latter protein being important not only for platelet adhesion, but also as a carrier for Factor VIII,. Even in the process ofclot dissolution, plasmin proteolyzes both fibrin and glycoprotein Tb, a vWF receptor, from the platelet surface (26) , thereby facilitating fibrin and platelet removal from the thrombus.
These interactions between platelets and coagulation proteins depend critically on their physical proximity. Platelets are readily incorporated into the fibrin thrombus (27) itself; and this in- corporation has been shown to depend on their interaction with polymerizing fibrin (28). In addition, fibrin polymers formed in the presence of platelets are larger than those formed in their absence (28) and patients with vWF deficiency produce thrombi of smaller volume than normal (29) .
It thus appears that the interaction of platelets with polymerizing fibrin is an important hemostatic event that serves to poise the events of primary and secondary hemostasis in optimal relationship to one another. In this paper, we show that vWF is the adhesive protein that mediates this platelet-fibrin interaction and that it does so by binding to fibrin monomer and to platelet surface glycoprotein lb. This observation provides a new and important example ofcoupling between primary and secondary hemostatic processes and offers a possible mechanism for the selective activation ofplatelet vWF receptors during hemostasis. We propose that this vWF-fibrin-platelet interaction augments flow-dependent platelet adhesion following vascular injury.
experiments pure human fibrinogen free of detectable fibronectin and vWF was kindly provided by Dr. Jacek Hawiger, New England Deaconess Hospital, Boston, MA. Sephacryl S-1000 was obtained from Pharmacia Fine Chemicals, Stockholm, Sweden.
Platelets. Venous blood was obtained from volunteers who had not ingested acetylsalicylic acid for at least 10 d and was anticoagulated with 13 mM sodium citrate. Platelet-rich plasma (PRP) was prepared by centrifugation at 160 g for 10 min. Platelet counts were determined with a Coulter counter (model F, Coulter Electronics, Inc., Hialeah, FL). Platelets were fixed with formalin (FP) according to published methods (30, 31) and stored at 4VC for up to 2 wk with no appreciable loss ofagglutinability to vWF and ristocetin.
Platelet aggregation. Platelet aggregation was monitored using a standard nephelometric technique (32) in which 0.4-ml aliquots ofplatelet suspensions were incubated at 370C and stirred at 900 rpm in a dualchannel aggregometer (Payton Associates, Inc., Buffalo, NY). Aggregation or agglutination was induced by addition of agonist and changes in light transmittance recorded using an XY-recorder (Omniscribe, Houston Instruments, Austin, TX).
vWFpreparation. vWFwas prepared from a cryoprecipitate ofhuman plasma as described previously (33) . vWF activity was determined by the ristocetin assay (34, 35) using FP. Only the earliest eluting fractions from the Sephacryl S-1000 column ofvWF were used in the experiments presented here to minimize fibrinogen and fibronectin contamination. These fractions contained the largest multimers ofvWF (with molecular weights between 5 and 10 X 106 D and larger material that could not be resolved by the standard electrophoretic method ofRuggeri and Zimmerman (36, 37) ; the size of these multimers was further analyzed by electron microscopy and quasielastic light scattering (38, 39) and found to range in contour length from 100 to 1,300 nm) and were found to have <0.2 ,g offibrinogen per 100 Mg ofvWF and < 1.5 Mug offibronectin per 100 ,ug of vWF, as determined in solid-phase immunoassays using immunoadsorbed polyclonal rabbit anti-human fibronogen and fibronectin antisera (Calbiochem-Behring Co.), respectively.
Glycocalicin preparation. Glycocalicin, the water-soluble fragment of platelet membrane glycoprotein Ib, was prepared as described previously (40) .
Platelet radioiodination. Both fresh and formalin-treated platelets were radioiodinated with '25I-Na by the lactoperoxidase method (41, 42) . Fresh platelets had a specific activity of 1.5 X I0' cpm/109 platelets, while '251-labeled FP had a specific activity of 2.6 X 107 cpm/109 FP. Both '25I-platelets and 125I-FP agglutinated normally on addition of 1.0 mg/ml ristocetin in the presence of as little as 8 Mg/ml of purified vWF. Protein radioiodination. vWF and highly purified fibrinogen were both iodinated using Iodo-beads. One Iodo-bead was incubated with 0.5-1.0 mCi of 1251I-Na (for vWF, glycocalicin, and fibrinogen) or of '3'INa (for vWF) at 250 for 15-20 min. To this was added 1.0 ml of 0.1 mg/ml protein in 10 mM Tris, pH 7.8, 0.15 M NaCI (TBS) and the incubation continued for 20-25 min with gentle rocking. The protein solution was then applied to a 10 X 0.7 cm Sephadex G-25 column that had been equilibrated with 1 ml of 5 mg/ml bovine serum albumin in TBS. Twelve 0.3-ml fractions were collected and assayed for total and 25% trichloroacetic acid-precipitable radioactivity. Routinely, column fractions five through eight contained maximal protein-bound counts with an 0. 1-0.2 ACi/Mg sp act. These fractions were either used immediately or stored at 4°C for up to 1 wk without appreciable loss of protein-bound counts.
Solublefibrin monomer preparation. Soluble fibrin monomer (SFM) was prepared by adding bovine thrombin at a final concentration of 2-3 U/ml to a 2-mg/ml solution of highly purified human fibrinogen in TBS with 2.5 mM GPRP added to inhibit polymerization (43). After incubation for 20 min at room temperature PPACK, a specific inhibitor of thrombin's amidolytic activity (44) , was added to a final concentration of 48 uM. Under these conditions, no appreciable fibrin polymer was detectable, either by gross inspection or by turbidity change at 350 nm (45) , for up to 1.5 h at room temperature. In the absence of GPRP, 95% of fibrinogen was clottable.
Assay ofplatelet andprotein incorporation in/fbrin clot. Suspensions of platelets (fresh platelets, FP, or radioiodinated fresh platelets or FP) at a total final concentration of 3-5 X 104/Ml in TBS were placed in 1-ml cylindrical glass cuvettes containing a 1.5 X 9 mm cylindrical stirring bar. Plasma, purified vWF, "3'I-vWF, purified fibrinogen, 1251-fibrinogen, or SFM were added, the volume was brought to 0.9 ml with TBS, and the suspension stirred at 900 rpm at 250C. Bovine thrombin or Bothrops atrox venom was then added and 25-Ml aliquots of the suspension were removed from the periphery ofthe solution away from the central vortex and evolving clot to determine residual, unincorporated radioactivity or, in some experiments, to perform directly platelet counts. The fibrin clot formed on the stirring bar and often extended to the meniscus of the solution through the center of the cuvette, but did not touch the sides of the cuvette where the samples were withdrawn.
In most cases, the fraction of total platelets incorporated in evolving thrombus was determined, either by measuring residual, unincorporated platelets or by determining radioactivity incorporated directly in the clot after washing the clot three times with TBS. Using both techniques, 98% of all radioactivity (free and incorporated in thrombus) was routinely recovered to within 2%. In a typical experiment using 5 X 104 FP/Ml, a 1:10 dilution of normal plasma, and 2 U/ml bovine thrombin, 49±5% of platelets were incorporated after 20 min at 250C. Using '31I-vWF at a total vWF concentration of 17 Mg/ml or '25I-flbrinogen at 280 Mg/ml under the same conditions, 13±1% or 40±5% ofthe added radioactivity was incorporated, respectively, by 20 min at 250C. In early experiments, Matrex beads (on the surface of which was 4.1 X 105 fibrin monomers/ bead) in a 0.4-ml total volume in TBS for 1 h with stirring at 900 rpm at 250C. At the end of the incubation period, 0.1 ml of the incubation suspension was layered over 0.2 ml of20% sucrose in TBS and centrifuged at 8,700 g for 2.5 min. The tip of the centrifuge tube was excised and radioactivity counted in order to measure binding. Nonspecific binding was determined by adding a 20-fold excess of unlabeled vWF and accounted for -27% ofthe total bound counts in this system. It is important to note that 251-,vWF bound to control, fibrinogen-immobilized or bovine serum albumin-immobilized Matrex beads nonspecifically, that is, linearly throughout the concentration range tested without achieving saturation and without displacement by a 20-fold excess of unlabeled YWF.
Binding ofglycocalicin to FM-Matrex and vWF. Similar experiments were performed using '25I-glycocalicin and FM-Matrex in the presence of (saturating) concentrations of vWF (20 ,g/ml). Increasing concentrations of glycocalicin (0.85 to 17 ug/ml) were incubated with 2.4 X 106 FM-Matrex beads in 0.3-ml total volume in TBS for 1 h with stirring at 900 rpm at 250C. At the end of the incubation period, 0.1 ml of the incubation suspension was layered over 0.2 ml of 20% sucrose in TBS and centrifuged at 8,700 g for 2.5 min. The tip of the centrifuge tube was excised and radioactivity counted in order to measure binding. Nonspecific binding was determined by adding a 20-fold excess of unlabeled glycocalicin and accounted for -76% of the total bound counts in this system. Using control fibrinogen-immobilized or bovine serum albuminimmobilized Matrex beads, '25I-glycocalicin bound nonspecifically only, that is, linearly over the concentration range tested without achieving saturation and without displacement by a 20-fold excess of unlabeled glycocalicin.
Protein determinations. Protein concentrations were determined by the method of Lowry and colleagues (47) .
Results
Dependence ofplatelet incorporation in evolvingfibrin thrombus on vWF. As shown in Table I , there is a direct relationship between the quantity of vWF present in plasma and the interaction of FP with polymerizing fibrin. When normal platelet-poor plasma was used as a source of vWF, 52±2% of total platelets were incorporated by 20 min. Using vWF-deficient plasma with no ristocetin cofactor activity, only 30±4% of total platelets were incorporated. Adding increasing concentrations ofpurified vWF, from 5 to 15 ,ug/ml, increased the extent ofincorporation of FP to that found with normal plasma.
Effect of vWF on extent and initial rate ofplatelet incorporation in evolvingfibrin clot. Fig. 1 shows the'interaction of 1251. FP with polymerizing fibrin as a function of time after addition of 2 U/ml of bovine'thrombin to a 1:10 dilution of normal or vWF-deficient plasma. Both the rate and extent of incorporation Figure 1 . Effect of vWF on time course of FP incorporation into fibrin thrombi. To 0.9 ml of a platelet suspension containing 5 X l04 1251 FP/Ml in 10% normal plasma or 10% vWF-deficient plasma was added 2 U/ml bovine thrombin and the change in unincorporated radioactivity determined at various times of incubation at 250C with stirring at 900 rpm. Each point represents the mean±SEM of three to five experiments done in duplicate.
ofFP were dramatically affected by vWF, its presence increasing the initial rate of incorporation -30-fold and the extent of incorporation 1.7-fold ( Fig. 1 and Table II ). Addition of vWF to 18 ,gg/ml partly restored the initial rate and completely restored the extent of incorporation (Table II) .
In order to assess better the molecular determinants of incorporation, the experiments listed in Table II 1251 fibrinogen showed no such dependence, 40±5% being converted to fibrin and incorporated in the fibrin-platelet thrombus using normal plasma, vWF-deficient plasma, or plasmin-treated FP. The incorporation of human serum albumin was similarly unaffected by the presence of vWF, with <1% being incorporated in the presence or absence of vWF (Table III) . All results are expressed as the mean±SEM of two experiments done in duplicate. Plasmas were diluted 1:10 in all experiments.
* 17 1g/ml vWF was used in these assays.
j 280 jig/ml fibrinogen was used in these assays. § 2 mg/ml albumin was used in these assays; in order to detect this small amount of incorporated protein, the clot was rinsed three times with TBS and counted directly.
Binding ofSFM to vWF. In order to demonstrate that SFM binds to vWF, 50 ,ug of vWF was incubated with both '25i-fibrinogen and I251-SFM for 5 min in 50 ,Au of TBS, then applied to a Sephacryl S-1000 column. As shown in Fig. 2, in Fig. 3 , glycocalicin elutes well within the column volume when applied by itself or with vWF or SFM. In the presence ofboth vWF and SFM (1:1:1 molar ratios), however, glycocalicin elutes at the void volume. These data in conjunction with those of Fig. 2 suggest that glycocalicin forms a ternary complex with SFM and vWF under the conditions of this experimental system.
Binding of vWF to FM-Matrex. In order to quantitate the binding of vWF to fibrin monomer, '25I-vWF was incubated with FM-Matrex and binding assessed as described in Methods. 
Discussion
The data presented here show that platelet incorporation in an evolving fibrin thrombus is dependent on vWF. Under the conditions of our in vitro system, the initial rate of incorporation is markedly reduced in the absence ofvWF. The extent ofplatelet incorporation is also reduced, but less dramatically. Purified vWF restores the initial rate and extent of incorporation. The void volume was determined using '25I-vWF and found to be 1.2 ml (fraction 6) and the column volume was determined using '25I-Na and found to be 7.2 ml (fraction 16 ). Niewiarowski and colleagues (48, 49) have previously shown that while erythrocytes are incorporated in polymerizing fibrin purely by nonspecific entrapment, platelets are incorporated both by entrapment and by specific binding to some intermediate species generated during the conversion of fibrinogen to fibrin. Our data suggest that this specific binding is mediated by vWF and, furthermore, that vWF accomplishes this by binding both to a receptor site on glycoprotein lb and to fibrin monomer.
The attenuation of platelet incorporation by a polyclonal anti-vWF antibody and by vWF-deficient plasma, as well as its restoration by addition of purified vWF, supports the role of vWF in this process. Formalin-fixation, under conditions that preserve glycoprotein Ib availability and affinity for vWF but impair glycoprotein IIb/IIIa function, does not inhibit the vWFdependent incorporation of platelets in evolving fibrin thrombi. In contrast, the observation that plasmin treatment of platelets, a process that cleaves glycoprotein lb from the platelet surface (26, 50) , as well as incubation with a monoclonal anti-glycoprotein lb antibody, markedly impair the vWF-dependent incorporation of platelets in evolving fibrin thrombi support the role ofglycoprotein lb as the vWF-receptor on the platelet surface in this system.
These experiments also demonstrate that vWF can bind to glycoprotein Ib in the absence of ristocetin. Although it is clear that the glycoprotein Ib-vWF-collagen interaction is critical for platelet adhesion in flowing blood, the physiologic mechanism that regulates vWF binding to glycoprotein Ib had not been defined prior to this study. Thrombin and ADP can initiate binding of both vWF and fibrinogen to glycoprotein IIb/IIIa, but, to date, the only agents found to facilitate vWF binding to glycoprotein Ib have been cationic polypeptides, such as ristocetin and poly-L-lysine (51) . The data presented here with purified proteins show that vWF binds to SFM and that only this binary complex can, in turn, bind to glycocalicin. Using fibrin monomer immobilized on Matrex beads, vWF was found to bind specifically and saturably with an approximate apparent KD of 15 ,ug/ ml. Glycocalicin bound to fibrin monomer immobilized on Matrex beads, as well, but only in the presence of vWF, suggesting that the binding of vWF to fibrin monomer supports glycocalicin binding either by producing a binding site comprised of fibrin and vWF epitopes or as a result of a conformational change in vWF or fibrin monomer induced by binding. The stoichiometry of binding is 1:1.3:0.8 fibrin monomer/vWF/glycocalicin. That greater than one molecule (monomer) ofvWF binds per complex suggests the possibility that a dimer of vWF is the important for the production of the ternary complex, but further studies are needed to clarify this possibility. These observations thus strongly suggest that SFM functions as a "ristocetin-equivalent" which, on binding to vWF, facilitates its binding to glycoprotein Ib. There is other evidence to support the role of vWF, polymerizing fibrin, and platelets in thrombus generation. In addition to the suggestion by Niewiarowski and colleagues (48, 49) that platelets are incorporated into polymerizing fibrin by specific receptor-mediated binding as well as entrapment, Turitto and associates (29) have demonstrated recently that at intermediate shear rates (-650-1,300 s-1) platelet adhesion to subendothelium in vWF-deficient plasma is normal, but thrombus dimensions are significantly reduced compared with both normal controls and hemophiliacs. In addition, they report that the deposition offibrin is essentially normal in this vWF-deficient plasma. Weiss and Rogers (52) showed that two patients with congenital afibrinogenemia had diminished platelet aggregation in response to ADP and epinephrine, and a prolonged bleeding time. This latter phenomenon could be explained by abnormal platelet aggregation, as well as abnormal platelet adhesion due to impaired production of SFM essential for platelet recruitment in the evolving platelet-fibrin thrombus.
The potential relevance of the observations first made in experiments with FP was confirmed by experiments using fresh platelets and B. atrox venom to produce fibrin. B. atrox venom does not affect the platelet surface nor induce platelet aggregation or the release reaction (53, 54) as thrombin does, but acts solely to convert fibrinogen to fibrin. While the low concentration of fibrinogen used in these experiments may be considered physiologically inappropriate, this concentration was chosen to slow the rate offibrin polymerization sufficiently so that the differences in initial rate of incorporation of platelets could be readily discerned. When higher concentrations of plasma were used, the effect on initial rate was less marked, but the effect on extent of incorporation persisted (Table I ). The actual physiologic relevance ofthese observations is difficult to determine with certainty since local concentrations ofall ofthe components-vWF, SFM, and glycocalicin/glycoprotein Ib-may vary greatly at sites of injury compared with their concentrations in normal plasma. Thus, the overall importance of the mechanism described here to hemostasis will have to await further experimentation in increasingly complex artificial systems.
The results of a study by Hantgan and colleagues (55) suggest that platelet activation is a prerequisite for binding to fibrin and that unactivated platelets only bind to polymerizing fibrin in a nonspecific manner through pure entrapment. This latter conclusion contradicts both our data and the data presented in many earlier studies (27, 28, 48, 49, 56 ) that both nonspecific entrapment and specific binding interactions between unactivated platelets and polymerizing fibrin promote platelet incorporation in evolving fibrin thrombus. The reasons for this difference between the work of Hantgan and colleagues and the present data may represent differences in experimental conditions. For example, Hantgan's group did not stir the suspension of platelets and polymerizing fibrin, while we and other experimenters (27, 28, 48, 49, 56) did; in addition, the fibrinogen used in Hantgan's experiments was labeled with the bulky, aromatic fluorophore, dansylcadaverine, the effect of which on protein-protein interactions in this complex system is not clear. In any case, the fact that activated platelets are known to bind fibrinogen (57) (58) (59) argues that activated platelets could, indeed, provide more binding sites than unactivated platelets for interaction with polymerizing fibrin, perhaps through glycoprotein IIb/IIIa in addition to glycoprotein Ib, thereby potentiating the extent of incorporation in evolving platelet-fibrin thrombus. Thus, in one sense, the data of Hantgan and colleagues (55) are not as much contradictory as complementary to the data presented here.
These data clearly demonstrate that vWF is incorporated into polymerizing fibrin by binding to SFM and that this binding facilitates binding of vWF to glycoprotein Ib. This incorporation of vWF in fibrin thrombus may enhance the number of platelets included in the thrombus and may augment further fibrin production by delivering Factor VIII; to the activated coagulation cascade.
